Press Resease

Hemophilia Treatment Market by Type (Hemophilia A, Hemophilia B, and Hemophilia C), by Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Antifibrinolytic Agents, and Desmopressin), and by Therapy (Replacement and Gene): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 23-Jul-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-4472 Status : Published

Global hemophilia treatment market expected to generate around USD 16,310 million by 2025, at a CAGR of around 6.24% between 2019 and 2025. The global hemophilia treatment market is growing due to increasing bleeding disorder prevalence and their rising severity, advancing medical knowledge, and the rising number of scientific research activities.

Description

The report covers a forecast and an analysis of the hemophilia treatment market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes the drivers and restraints of the hemophilia treatment market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the hemophilia treatment market on a global and regional level.

In order to give the users of this report a comprehensive view of the hemophilia treatment market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the hemophilia treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new Type launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the hemophilia treatment market on a global and regional basis.

The study provides a decisive view of the hemophilia treatment market by segmenting it based on type, product, therapy, and region. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some key players operating in the global hemophilia treatment market are Pfizer, Baxalta, Baxter International, CSL Ltd., Octapharma, Grifols, Novo Nordisk, Kedrion, Bayer, Biogen Idec, and Hospira.

This report segments the global hemophilia treatment market into:

Global Hemophilia Treatment Market: By Type

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C

Global Hemophilia Treatment Market: By Product

  • Recombinant Coagulation Factor Concentrates
  • Plasma Derived Coagulation Factor Concentrates
  • Antifibrinolytic Agents
  • Desmopressin

Global Pediatrics Healthcare Market: By Therapy

  • Replacement Therapy
  • Gene Therapy

Global Hemophilia Treatment Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Hemophilia Treatment Market Revenue, 2016-2025 (USD Million)
    • 2.2. Global Hemophilia Treatment Market: Snapshot
  •  
  • Chapter 3. Hemophilia Treatment Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Hemophilia Treatment Market Drivers: Impact analysis
      • 3.2.2. Increasing incidences of bleeding disorders and their rising severity
      • 3.2.3. Technological Advancements
    • 3.3. Market Restraints
      • 3.3.1. Limited access to treatment
    • 3.4. Opportunities
      • 3.4.1. Advancements in gene therapy
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Type
      • 3.6.2. Market attractiveness analysis, by Product
      • 3.6.3. Market attractiveness analysis, by Therapy
      • 3.6.4. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Hemophilia Treatment Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Hemophilia Treatment Market: Company Market Share, 2018
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Type Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
  •  
  • Chapter 5. Global Hemophilia Treatment Market - Type Analysis
    • 5.1. Global Hemophilia Treatment Market: Type overview
      • 5.1.1. Global Hemophilia Treatment Market revenue share, by Type, 2018 and 2025
    • 5.2. Hemophilia A
      • 5.2.1. Global Hemophilia Treatment Market for Hemophilia A, 2016-2025 (USD Million)
    • 5.3. Hemophilia B
      • 5.3.1. Global Hemophilia Treatment Market for Hemophilia B, 2016-2025 (USD Million)
    • 5.4. Hemophilia C
      • 5.4.1. Global Hemophilia Treatment Market for Hemophilia C, 2016-2025 (USD Million)
  •  
  • Chapter 6. Global Hemophilia Treatment Market - Product Analysis
    • 6.1. Global Hemophilia Treatment Market: Product overview
      • 6.1.1. Global Hemophilia Treatment Market revenue share, by Product, 2018 and 2025
    • 6.2. Recombinant Coagulation Factor Concentrates
      • 6.2.1. Global Hemophilia Treatment Market for Recombinant Coagulation Factor Concentrates, 2016-2025 (USD Million)
    • 6.3. Plasma Derived Coagulation Factor Concentrates
      • 6.3.1. Global Hemophilia Treatment Market for Plasma Derived Coagulation Factor Concentrates, 2016-2025 (USD Million)
    • 6.4. Antifibrinolytic Agents
      • 6.4.1. Global Hemophilia Treatment Market for Antifibrinolytic Agents, 2016-2025 (USD Million)
    • 6.5. Desmopressin
      • 6.5.1. Global Hemophilia Treatment Market for Desmopressin, 2016-2025 (USD Million)
  •  
  • Chapter 7. Global Hemophilia Treatment Market - Therapy Analysis
    • 7.1. Global Hemophilia Treatment Market: Treatment overview
      • 7.1.1. Global Hemophilia Treatment Market revenue share, by Treatment, 2018 and 2025
    • 7.2. Replacement Therapy
      • 7.2.1. Global Hemophilia Treatment Market for Replacement Therapy, 2016-2025 (USD Million)
    • 7.3. Gene Therapy
      • 7.3.1. Global Hemophilia Treatment Market for Gene Therapy, 2016-2025 (USD Million)
  •  
  • Chapter 8. Global Hemophilia Treatment Market - Regional Analysis
    • 8.1. Global Airport Logistics System: Regional overview
      • 8.1.1. Global Hemophilia Treatment Market revenue share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
      • 8.2.2. North America Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
      • 8.2.3. North America Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.2.4.2. The U.S. Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.2.4.3. The U.S. Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.2.5.2. Rest of North America Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.2.5.3. Rest of North America Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
      • 8.3.2. Europe Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
      • 8.3.3. Europe Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.3.4. Germany
        • 8.3.4.1. Germany Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.3.4.2. Germany Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.3.4.3. Germany Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.3.5. UK
        • 8.3.5.1. UK Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.3.5.2. UK Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.3.5.3. UK Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.3.6.2. France Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.3.6.3. France Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest of Europe Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.3.7.2. Rest of Europe Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.3.7.3. Rest of Europe Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
      • 8.4.2. Asia Pacific Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
      • 8.4.3. Asia Pacific Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.4.4. China
        • 8.4.4.1. China Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.4.4.2. China Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.4.4.3. China Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.4.5.2. Japan Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.4.5.3. Japan Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.4.6. India
        • 8.4.6.1. India Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.4.6.2. India Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.4.6.3. India Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.4.7.2. Rest of Asia Pacific Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.4.7.3. Rest of Asia Pacific Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
      • 8.5.2. Latin America Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
      • 8.5.3. Latin America Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.5.4.2. Brazil Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.5.4.3. Brazil Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
        • 8.5.5.2. Rest of Latin America Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
        • 8.5.5.3. Rest of Latin America Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Hemophilia Treatment Market Revenue, by Type, 2016-2025 (USD Million)
      • 8.6.2. The Middle East and Africa Hemophilia Treatment Market Revenue, by Product, 2016-2025 (USD Million)
      • 8.6.3. The Middle East and Africa Hemophilia Treatment Market Revenue, by Therapy, 2016-2025 (USD Million)
  •  
  • Chapter 9. Company Profile
    • 9.1. Pfizer
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Type Portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Baxalta
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Type Portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. Baxter International
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Type Portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. CSL Ltd.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Type Portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Octapharma
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Type Portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. Grifols
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Type Portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. Novo Nordisk
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Type Portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Kedrion
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Type Portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Bayer
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Type Portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Biogen Idec
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Type Portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
    • 9.11. Hospira
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Type Portfolio
      • 9.11.4. Business strategy
      • 9.11.5. Recent developments

Methodology

Free Analysis

Hemophilia is commonly a genetic rare bleeding disorder that restricts blood clotting in a proper way, as it deficiencies adequate blood-clotting proteins (clotting factor). This condition tends to occur mainly in males. People with hemophilia do not bleed any faster than normal but can bleed for an extended time after an injury than anyone would have if their blood clotted normally. The constant bleeding can damage organs and tissues and may even be life-threatening. The three different clotting factor deficiencies are Hemophilia A, B, and C. Hemophilia A is the most common type that does not have sufficient Clotting Factor VIII (factor eight). Hemophilia B and C occur due to deficiency of factor IX and factor XI, respectively. Hemophilia treatment involves the replacement of the specific needed clotting factor via a tube inserted in a vein.

The global hemophilia treatment market is growing due to increasing bleeding disorder prevalence and their rising severity, advancing medical knowledge, and the rising number of scientific research activities. Additionally, the increasing use of prophylactic treatment for hemophilia, invention of novel coagulating factors, technological advancements, flourishing biotechnology sector, increasing awareness among people, escalating research and development focused on identifying curative agents are other key factors driving the global hemophilia treatment market. Furthermore, campaigns, investments, and supportive initiatives undertaken by governments globally to provide important healthcare are also propelling the hemophilia treatment market development. However, the high treatment costs, stringent government regulations, and lack of available medicines may restrain the hemophilia treatment market growth.

The hemophilia treatment market is fragmented on the basis of type, product, and therapy. Based on type, the market includes Hemophilia A, B, and C. By product, the market is classified into desmopressin, plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, and antifibrinolytic agents. The therapy segment of the market comprises replacement and gene therapy.

North America dominated the global hemophilia treatment market in 2018, due to the increasing prevalence of bleeding disorder and their rising severity, rising preference toward prophylaxis treatment, the rising ability of effective gene therapy, and the regional presence of key market players. North America is estimated to maintain its top position over the forecast time period. Europe contributed the second largest revenue share in 2018 to the global hemophilia treatment market, due to the increasing prevalence of Hemophilia A, technological advancements, and rising investments in R&D for hemophilia products. The Asia Pacific hemophilia treatment market will show the highest CAGR over the forecast time period, owing to the increasing prevalence of hemophilia disease and growing use of recombinant products.

Some key players operating in the global hemophilia treatment market are Pfizer, Baxalta, Baxter International, CSL Ltd., Octapharma, Grifols, Novo Nordisk, Kedrion, Bayer, Biogen Idec, and Hospira.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social